Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 490 results for %s

  1. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  2. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 March 2017

  3. Peripheral nerve-field stimulation for chronic low back pain (HTG309)

    Evidence-based recommendations on peripheral nerve-field stimulation for chronic low back pain. This involves implanting electrodes in the back, connected to a neurostimulator under the skin to mask the back pain by modulating the transmission of pain signals to the brain.

    HealthTech guidance
    Published
    27 March 2013
    View recommendations

    Sections for HTG309

  4. Intrapartum care (NG235)

    This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

    NICE guideline
    Last updated
    14 November 2025
    View recommendations

    Sections for NG235

  5. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  6. Pregnancy and neonates: hip screening (IND77)

    This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96

    Network / system level indicators
    Published
    26 October 2021

  7. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

    Clinical guideline
    Last updated
    7 February 2017
    View recommendations

    Sections for CG146

  8. Evidence summaries: new medicines – Interim process statement (PMG1)

    This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs

  9. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    How this decision aid can help 3 Diagram based on original developed by N H S Lothian. Used with permission. Pelvic bone Vagina Urethra...

  10. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    27 April 2011
    View recommendations

    Sections for TA220

  11. Constipation in children and young people: diagnosis and management (CG99)

    This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.

    Clinical guideline
    Last updated
    13 July 2017
    View recommendations

    Sections for CG99

  12. Cancer: bowel screening (60 to 74 years) (IND64)

    This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83

    Network / system level indicators
    Last updated
    31 October 2023

  13. Microwave ablation of hepatocellular carcinoma (HTG138)

    Evidence-based recommendations on microwave ablation of hepatocellular carcinoma. This involves using heat from microwave energy to destroy the cancer cells.

    HealthTech guidance
    Published
    28 March 2007
    View recommendations

    Sections for HTG138

  14. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  15. Autism (QS51)

    This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS51